Study to Assess Efficacy & Safety of Bulevirtide in Combination With

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04170452` - Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta
Withdrawn	`NCT05953545` - Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis	Phase 2
Active, not recruiting	`NCT03852719` - Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)	Phase 3

See also

Status

Clinical Trial

Phase

Enrolling by invitation

NCT04170452 - Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta

Withdrawn

NCT05953545 - Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis

Phase 2

Active, not recruiting

NCT03852719 - Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)

Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03852433
Study type	Interventional
Source	Gilead Sciences
Contact
Status	Completed
Phase	Phase 2
Start date	May 31, 2019
Completion date	September 23, 2022

Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms